ZANTAC Drug Patent Profile

Which patents cover Zantac, and when can generic versions of Zantac launch?

Zantac is a drug marketed by Pai Holdings Pharm, Glaxo Grp Ltd, Glaxosmithkline, and Chattem Sanofi. and is included in nine NDAs.

The generic ingredient in ZANTAC is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac

A generic version of ZANTAC was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Summary for ZANTAC

US Patents:	0
Applicants:	4
NDAs:	9

US Patents and Regulatory Information for ZANTAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pai Holdings Pharm	ZANTAC	ranitidine hydrochloride	INJECTABLE;INJECTION	019090-001	Oct 19, 1984		DISCN	Yes	No
Chattem Sanofi	ZANTAC 150	ranitidine hydrochloride	TABLET;ORAL	021698-002	Mar 13, 2007		DISCN	Yes	No
Glaxo Grp Ltd	ZANTAC 150	ranitidine hydrochloride	GRANULE, EFFERVESCENT;ORAL	020251-002	Mar 31, 1994		DISCN	No	No

International Patents for ZANTAC

See the table below for patents covering ZANTAC around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	33792
Spain	505951
Denmark	167923

Zantac (Ranitidine) Investment Scenario and Fundamentals Analysis

Last updated: February 3, 2026

What is the current status of Zantac and its market potential?

Zantac (ranitidine) was once a leading medication in the gastrointestinal (GI) sector, primarily used to treat ulcers and gastroesophageal reflux disease (GERD). Its sales peaked before safety concerns led to its market withdrawal, complicating its investment outlook.

In April 2020, the U.S. Food and Drug Administration (FDA) requested all Ranitidine products be withdrawn from the market due to contamination with N-nitrosodimethylamine (NDMA), a probable human carcinogen. This toll on global supply chains diminishes therapeutic revenue streams and registers significant downside risk.

How did safety issues affect Zantac’s market?

• Market withdrawal: Ranitidine was withdrawn in the U.S., Europe, and Canada between April 2020 and mid-2021.
• Sales impact: Prior to withdrawal, Zantac generated approximately $1.2 billion annually globally (IQVIA, 2019).
• Legal liabilities: Thousands of lawsuits alleged carcinogenicity, leading to potential liabilities and tarnished reputation if reintroduced.

Are there ongoing or potential development pathways for Zantac?

Pharmaceutical companies are exploring reformulation or alternative manufacturers. Several firms have initiated research to remove NDMA impurities or develop new H2-receptor antagonists (H2RAs).

• Regulatory hurdles: Any attempt to reintroduce ranitidine faces significant regulatory scrutiny, as many agencies have not lifted the market bans.
• Patent landscape: Original patents expired decades ago, leading to numerous generic manufacturers, yet no authorized reformulation has received market approval.

What are the key health-sector regulators’ positions?

• FDA: Confirms NDMA levels in ranitidine poses health risks; no plans to re-approve ranitidine in its original form.
• EMA: Similarly advised against re-marketing without reformulation.
• Global regulatory stance: Strict, with no indication of re-approval unless new, safer formulations are developed and validated.

What are investment implications based on public data?

1. Market opportunity is limited: With Zantac withdrawn, no direct sales exist under the original formulation.
2. Reformulation prospects are uncertain: Development costs and regulatory hurdles pose high barriers.
3. Generic manufacturing remains unaffected: Currently, multiple generic brands exist, but sales are declining and uncertain post-approval bans.
4. Legal liabilities present risks: Past litigations have resulted in significant financial penalties for makers linked to NDMA contamination.

Financial considerations:

Factor	Impact	Data Source
Revenue loss from withdrawal	90% decline since 2020	IQVIA [1]
Cost of reformulation	Estimated $100-200 million per candidate	Industry estimates
Legal liabilities	Potential billions in lawsuits	Plaintiffs' settlements, industry reports

Are there alternative options for investors?

• Focus on companies involved in reformulation efforts or developing new H2RAs with safer profiles.
• Invest in generic companies with diversified portfolios that include GI drugs.
• Monitor regulatory developments for any re-approvals or new formulations, which remain unlikely in the short term.

What are the legal and regulatory risks?

• Litigation: Pending or past lawsuits could result in substantial penalties.
• Regulatory rejection or delays: Obvious barriers without clear pathways to re-approval.
• Market perception: Negative public perception could influence pharmaceutical strategies.

How does Zantac compare to similar drugs?

Drug	Class	Sales Peak (USD million)	Post-Withdrawal Status	Regulatory Outlook
Zantac (ranitidine)	H2- receptor antagonist	1200 (2019)	Withdrawn worldwide	No re-approval unless reformulated and safety validated
Famotidine	H2- receptor antagonist	Estimated $300 (US)	Available globally	No major restrictions; market dominance for some indications remains

Conclusions on Investment Scenario

Zantac's original formulation poses minimal direct investment appeal due to market withdrawal and safety risks. Opportunities may exist in reformulation research or generic manufacturing, but high R&D costs and regulatory uncertainties pose barriers. Litigation liabilities remain a concern, and regulatory agencies clearly oppose re-approval in its existing form.

Key Takeaways

• Zantac is effectively off-market owing to safety concerns.
• Reintroduction hinges on reformulation that addresses NDMA contamination.
• Current investments should focus on firms developing safer alternatives or involved in reformulation efforts.
• Market opportunities are limited and high risk due to procedural, legal, and regulatory hurdles.
• The pharmaceutical landscape indicates limited near-term upside for traditional ranitidine products.

FAQs

1. Could Zantac return to the market in the future?
Reintroduction depends on reformulation, safety validation, and regulatory approval. No confirmed pathways exist currently.

2. What legal liabilities do companies face with past Zantac sales?
Companies involved in manufacturing or marketing Zantac faced thousands of lawsuits. Total settlements could reach over $20 billion, according to industry estimates.

3. Are there any ongoing research efforts to reformulate Zantac?
Several pharmaceutical firms are exploring reformulation, but none have received regulatory approval to date.

4. How do regulatory bodies’ positions impact potential investment?
Strict rejection of original formulations and significant hurdles for reformulation diminish viability for direct investment in Zantac.

5. What alternative GI drugs should investors consider?
Investors should evaluate other H2RAs like famotidine or proton pump inhibitors (PPIs) with safer profiles and established regulatory approval.

---

References

[1] IQVIA, 2019. Global Sales Data.
[2] FDA, 2020. Consumer Alert on Ranitidine.
[3] EMA, 2020. Safety Data on Ranitidine.